E. Calcagno

Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory

E. Fedele, A. Palmeri, O. Arancio, 2017, The Journal of Neuroscience.

Development of novel phosphodiesterase 5 inhibitors for the therapy of alzheimer's disease.

Elentina K. Argyrousi, O. Arancio, D. Landry, 2020, Biochemical pharmacology.

Tau is not necessary for amyloid-beta-induced synaptic and memory impairments.

Elentina K. Argyrousi, P. Fraser, O. Arancio, 2020, The Journal of clinical investigation.

Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease

Elentina K. Argyrousi, E. Fedele, O. Arancio, 2017, Scientific Reports.

Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade

Elentina K. Argyrousi, O. Arancio, D. Puzzo, 2019, Molecular Neurodegeneration.

Investigating the amyloid-beta enhancing effect of cGMP in neuro2a cells

E. Fedele, R. Ricciarelli, M. Pronzato, 2017, Mechanisms of Ageing and Development.

Tau is not necessary for amyloid-β – induced synaptic and memory impairments

Elentina K. Argyrousi, P. Fraser, O. Arancio, 2020 .